Zero deaths from tuberculosis: Progress, reality, and hope

The Lancet Infectious Diseases

Volumn 13, Issue 4, 2013, Pages 285-287

  Zumla, Alimuddin ^a,b   Kim, Peter ^c   Maeurer, Markus ^d   Schito, Marco ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETIC POLYMORPHISM; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASES; HEALTH POLICY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84875602629     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70039-2     Document Type: Letter

References (7)

1. Global tuberculosis report 2012 2012, WHO, World Health Organisation, Geneva, (accessed Dec 27). http://www.who.int/tb/publications/global_report/en/index.html.
2. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70008-2.
3. Wallis RS, Kim PS, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70034-3.
4. Marais B, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70015-X.
5. Wells WA, Boehme CC, Cobelens FGJ, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70025-2.
6. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70030-6.
7. Boulanger RF, Seidel S, Lessem E, et al. Engaging communities in tuberculosis research. Lancet Infect Dis 2013, on behalf of the Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup, publshed online March 24. http://www.dx.doi.org/10.1016/S1473-3099(13)70042-2.